MBRX

Moleculin Biotech, Inc.

0.60 USD
-0.01 (-2.20%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Moleculin Biotech, Inc. stock is up 19.3% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 7 February’s closed higher than January.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the. treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in clinical trials for brain tumors and pediatric brain tumors.